1 143 144 145
Number of results: 2898
Date Compound Product name Company Disease Action mechanism Type of Information
0000-00-00 rasagiline mesylate rasagiline mesylate Takeda Pharmaceutical (Japan) Parkinson’s disease Rasagiline is a monoamine oxidase B (MAO-B) inhibitor. By irreversibly binding to MAO-B, it prevents the breakdown of dopamine in… Submission of an NDA
0000-00-00 eculizumab Soliris® Alexion Europe (Switzerland) myasthenia gravis, refractory generalized myasthenia gravis  in patients who are anti-acetylcholine receptor (AChR) antibody-positive monoclonal antibody. Eculizumab is a recombinant humanized monoclonal IgG2/4 antibody that specifically binds to the complement protein C5, inhibiting its… Granting of a Market Authorisation in Japan
0000-00-00 Plant acquisition
0000-00-00 Compound: Product name: sadasd dsadasdasd asdasdasdas Plant acquisition
0000-00-00 hj hjgh j vhv j Validation of a production plant
0000-00-00 Compound: bestttt asdasdasda asdasdasdas adsasdasdas Plant acquisition
0000-00-00 test test test test test Grant
0000-00-00 humanised IgG4 monoclonal antibody to the human toll-like receptor type 2 OPN-305 Opsona Therapeutics (Ireland) myelodysplastic syndromes monoclonal antibody. OPN-305 is a novel proprietary humanized IgG4 monoclonal antibody (MAb) against Toll-Like Receptor 2 (TLR2), a target within… Granting of the orphan status in the EU
0000-00-00 pppppppppp
0000-00-00 Compound: bestttt vkh vki Action_mechanism: Company acquisition
0000-00-00 Compound: bestttt Laboratory Indication Action_mechanism:
0000-00-00 knjnlnlnln Product name:lknk nl nl lnl Licensing agreement
0000-00-00 test Establishment of a new subsidiary in the EU
0000-00-00 assay service for understanding the impact of point mutations on protein therapeutic activity MutaMap™ ProImmune (UK) MutaMap is an in vitro assay system that explores the effect of deliberate point mutations on protein activity by substituting… Product launch
0000-00-00 SHP654 (BAX 888) • gene therapy. SHP654 (BAX 888) is an investigational factor VIII (FVIII) gene therapy intended to treat hemophilia A using a… Granting of the orphan status in the US
0000-00-00 (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide zanubrutinib (BGB-3111) - (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide BeiGene (China) relapsed/refractory mantle cell lymphoma (MCL) inhibitor of Bruton’s tyrosine kinase (BTK). Zanubrutinib (BGB-3111) is an investigational small molecule inhibitor of Bruton’s tyrosine kinase (BTK) that… Acceptation for review of a NDA
0000-00-00 engineered recombinant human acid alpha-glucosidase (rhGAA) AT-GAA (ATB200/AT2221) Amicus Therapeutics (USA - NJ) Pompe disease enzyme replacement therapy. ATB200 is an engineered recombinant human acid alpha-glucosidase (rhGAA) enzyme with an optimized carbohydrate structure, administered in combination with a… Submission of a Market Application in the US